Department of Immunology 2nd Medical School Charles University and University Hospital Motol
2nd Medical School Charles University University Hospital Motol
czech  |  english
SEARCH
Teaching Research Routine Lab  Outpatient clinic  Seminars ESID Primary
immunodeficiencies
History Contacts


PhD study Publications Abstracts Projects Grants Working groups Lab equipment

Research  >  Working groups

 

Primary immunodeficiencies

Research aim


The aim of research projects in the field of primary immunodeficiencies (PIDs) is the study of immune processes altered as a result of inborn genetic disorders.

DiGeorge syndrome


This research project is focused on a cohort of patients with diGeorge syndrome, trying to map the immune system in these patients with thymic dysplasia of various degrees. Aside from evaluating the development of T-lymphocytes, we also examine the development of other cell lines, such as B-lymphocytes, but also cells of the innate immunity. A new and exciting sub-project is focused directly on analysis of thymic tissue and its function both in general and in diGeorge syndrome in particular.

Immune dysregulation


Other research projects encompass cohorts of patients with CVID, activated PI3-kinase syndrome (APDS) and other immunodeficiencies characterized mainly by immune system dysregulation. These projects are more clinically focused and map the mechanisms of immune dysregulation. The primary end-goal is, as always, finding new and more targetted modern therapies of these syndromes. In 2016, the PID working group with the Department of Immunology took part in a first-phase clinical trial organized by Novartis, where one of our patients was the first in Europe to receive a specific PI3K inhibitor, suppressing the effects of PI3-kinase and thus offsetting and treating his gain-of-function mutation. The study will continue with an extension and later on phase-two, planned for the coming years.

Cooperation


The PID working group with the Department of Immunology collaborates with other groups both in the Czech Republic and internationally. The most important partners are the Department of Pediatric Hematology and Oncology and its CLIP laboratory as a part of the University Hospital in Motol, the Department of Clinical Immunology and Allergology as a part of the Saint Anne Hospital and Masaryk University in Brno and the Primary Immunodeficiency Working Party with ČSAKI (Czech Society of Allergology and Clinical Immunology) which involves centers all around the Czech Republic. On the international scale, this working group is a part of ESID, the European Society for Immunodeficiencies (more on our involvement with ESID can be found here and here).

Principal investigators


  • Prof. MUDr. Anna Šedivá, DSc.
  • MUDr. Jana Kayserová, PhD
  • MUDr. Adam Klocperk
  • MUDr. Tomáš Milota
  • MUDr. Radana Zachová

 

Immunotherapy

Research Aim: Long term goal of the group of tumor immunotherapy is the development of dendritic cell based cancer vaccine. Administration of this vaccine should induce tumor cell-specific induce response and contribute to current treatment options.
This project was completed in March 2014, when two clinical studies aimed on treatment of prostate cancer and ovarian cancer were finished in University hospital Motol. Dendritic cell biology and their use in the immunotherapy of tumors have been studied at the Institute of Immunology for more than 10 years as documented by the list of publications . Further development and production of dendritic cells based vaccines was taken over by biotechnological company SOTIO.

Principal Investigators prof. Jiřina Bartůňková, M.D., Ph.D., MBA., Radek Špíšek, M.D., Ph.D.

Financial support: Research of dendritic cells at the Institute of Immunology, Charles University, 2nd Medical School has been supported by grants from Ministry of Education, grant agencies, grants form European Union.

Co jsou superčisté prostory
Cell therapy unit
DOC file (48 kB)

PRINT PAGE
TOP

 


Date of last update: 19.09.2017

© 2017 Department of Immunology, All rights reserverd.   |   tel.: +420 224 435 961   |   fax: +420 224 435 962   |   webmaster